Nurix Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 284
- Market Cap
- $1.5B
- Website
- http://www.nurixtx.com
- Introduction
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company w...
Relative Bioavailability of NX-5948 Tablets Vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
- Conditions
- Interventions
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06717269
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06691828
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06593457
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 292
- Registration Number
- NCT05131022
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
A Study of DeTIL-0255 in Adults With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05107739
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
A Study of NX-1607 in Adults With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 345
- Registration Number
- NCT05107674
- Locations
- 🇬🇧
Churchill Hospital, Oxford, United Kingdom
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Nurix Therapeutics, Inc.
- Target Recruit Count
- 266
- Registration Number
- NCT04830137
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸University of California San Francisco Medical Center, San Francisco, California, United States